British guidelines on managing hypertension. Provide evidence, progress, and an occasional missed opportunity
- PMID: 10473460
- PMCID: PMC1116478
- DOI: 10.1136/bmj.319.7210.589
British guidelines on managing hypertension. Provide evidence, progress, and an occasional missed opportunity
Comment in
-
Management of hypertension. Non-medical remedies should be considered first.BMJ. 2000 Feb 26;320(7234):577-8; author reply 579. BMJ. 2000. PMID: 10744401 No abstract available.
-
Management of hypertension. "Mortality" is preferable to "major disease end points".BMJ. 2000 Feb 26;320(7234):578; author reply 579. BMJ. 2000. PMID: 10744402 No abstract available.
-
Management of hypertension. Evidence shows that calcium antagonists reduce cardiovascular end points in diabetic patients.BMJ. 2000 Feb 26;320(7234):578; author reply 579-80. BMJ. 2000. PMID: 10744403 No abstract available.
-
Management of hypertension. Trials showing no reduction in mortality do not receive same exposure.BMJ. 2000 Feb 26;320(7234):578-9; author reply 579-80. BMJ. 2000. PMID: 10744405 No abstract available.
Comment on
-
British Hypertension Society guidelines for hypertension management 1999: summary.BMJ. 1999 Sep 4;319(7210):630-5. doi: 10.1136/bmj.319.7210.630. BMJ. 1999. PMID: 10473485 Free PMC article. No abstract available.
References
-
- Ramsay LE, Wallis EJ, Yeo WW, Jackson PR. The rationale for differing national recommendations for the treatment of hypertension. Am J Hypertens. 1998;11:79S–88S. - PubMed
-
- Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens. 1999;17:151–183. - PubMed
-
- Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413–2446. - PubMed
-
- Psaty BM, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Rosendaal FR, et al. Surrogate endpoints, health outcomes, and the drug approval process for the treatment of risk factors for cardiovascular disease. JAMA. 1999;282:786–790. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical